nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—PLK1—malignant glioma	0.688	1	CbGaD
Ruxolitinib—Haemorrhage intracranial—Temozolomide—malignant glioma	0.00199	0.0965	CcSEcCtD
Ruxolitinib—GRK7—retina—malignant glioma	0.00194	0.0193	CbGeAlD
Ruxolitinib—Myelosuppression—Carmustine—malignant glioma	0.0018	0.0873	CcSEcCtD
Ruxolitinib—Myelosuppression—Temozolomide—malignant glioma	0.00174	0.0844	CcSEcCtD
Ruxolitinib—ANKK1—telencephalon—malignant glioma	0.00163	0.0163	CbGeAlD
Ruxolitinib—RPS6KA6—embryo—malignant glioma	0.00149	0.0149	CbGeAlD
Ruxolitinib—GRK1—retina—malignant glioma	0.0014	0.014	CbGeAlD
Ruxolitinib—RPS6KA6—brainstem—malignant glioma	0.00137	0.0136	CbGeAlD
Ruxolitinib—BMPR2—blood vessel—malignant glioma	0.00134	0.0134	CbGeAlD
Ruxolitinib—GRK1—telencephalon—malignant glioma	0.00129	0.0129	CbGeAlD
Ruxolitinib—PRKCE—telencephalon—malignant glioma	0.00126	0.0126	CbGeAlD
Ruxolitinib—PLK3—embryo—malignant glioma	0.00125	0.0124	CbGeAlD
Ruxolitinib—Herpes zoster—Temozolomide—malignant glioma	0.00108	0.0526	CcSEcCtD
Ruxolitinib—JAK2—blood vessel—malignant glioma	0.000964	0.00961	CbGeAlD
Ruxolitinib—JAK1—embryo—malignant glioma	0.000956	0.00953	CbGeAlD
Ruxolitinib—DCLK1—embryo—malignant glioma	0.000956	0.00953	CbGeAlD
Ruxolitinib—CAMK1—telencephalon—malignant glioma	0.000948	0.00945	CbGeAlD
Ruxolitinib—PHKG2—brainstem—malignant glioma	0.00085	0.00847	CbGeAlD
Ruxolitinib—CAMK1D—retina—malignant glioma	0.000825	0.00822	CbGeAlD
Ruxolitinib—ROCK1—embryo—malignant glioma	0.000823	0.0082	CbGeAlD
Ruxolitinib—HIPK2—brainstem—malignant glioma	0.000818	0.00815	CbGeAlD
Ruxolitinib—JAK1—telencephalon—malignant glioma	0.000778	0.00775	CbGeAlD
Ruxolitinib—DCLK1—telencephalon—malignant glioma	0.000778	0.00775	CbGeAlD
Ruxolitinib—PRKG2—central nervous system—malignant glioma	0.000769	0.00767	CbGeAlD
Ruxolitinib—CAMK1—medulla oblongata—malignant glioma	0.000745	0.00742	CbGeAlD
Ruxolitinib—DAPK2—telencephalon—malignant glioma	0.000742	0.00739	CbGeAlD
Ruxolitinib—DYRK1A—brainstem—malignant glioma	0.000736	0.00733	CbGeAlD
Ruxolitinib—GRK1—central nervous system—malignant glioma	0.000734	0.00731	CbGeAlD
Ruxolitinib—BMPR2—brainstem—malignant glioma	0.000733	0.0073	CbGeAlD
Ruxolitinib—ROCK1—retina—malignant glioma	0.000728	0.00725	CbGeAlD
Ruxolitinib—HIPK2—telencephalon—malignant glioma	0.000726	0.00723	CbGeAlD
Ruxolitinib—PRKCE—central nervous system—malignant glioma	0.000718	0.00716	CbGeAlD
Ruxolitinib—PRKCE—cerebellum—malignant glioma	0.000702	0.007	CbGeAlD
Ruxolitinib—DAPK3—telencephalon—malignant glioma	0.000697	0.00695	CbGeAlD
Ruxolitinib—RPS6KA6—central nervous system—malignant glioma	0.00069	0.00688	CbGeAlD
Ruxolitinib—PLK1—central nervous system—malignant glioma	0.00069	0.00688	CbGeAlD
Ruxolitinib—MAST1—central nervous system—malignant glioma	0.00069	0.00688	CbGeAlD
Ruxolitinib—RPS6KA6—cerebellum—malignant glioma	0.000675	0.00672	CbGeAlD
Ruxolitinib—MAST1—cerebellum—malignant glioma	0.000675	0.00672	CbGeAlD
Ruxolitinib—ROCK1—telencephalon—malignant glioma	0.00067	0.00667	CbGeAlD
Ruxolitinib—CAMK1—spinal cord—malignant glioma	0.000664	0.00662	CbGeAlD
Ruxolitinib—CAMK2G—brainstem—malignant glioma	0.000656	0.00654	CbGeAlD
Ruxolitinib—DCLK3—central nervous system—malignant glioma	0.000654	0.00652	CbGeAlD
Ruxolitinib—DYRK1A—telencephalon—malignant glioma	0.000653	0.00651	CbGeAlD
Ruxolitinib—BMPR2—telencephalon—malignant glioma	0.00065	0.00648	CbGeAlD
Ruxolitinib—LRRK2—brainstem—malignant glioma	0.00065	0.00648	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000613	0.0297	CcSEcCtD
Ruxolitinib—JAK1—medulla oblongata—malignant glioma	0.000611	0.00609	CbGeAlD
Ruxolitinib—DCLK1—medulla oblongata—malignant glioma	0.000611	0.00609	CbGeAlD
Ruxolitinib—PRKG2—brain—malignant glioma	0.000611	0.00609	CbGeAlD
Ruxolitinib—RET—embryo—malignant glioma	0.000609	0.00606	CbGeAlD
Ruxolitinib—CAMK1D—medulla oblongata—malignant glioma	0.000596	0.00594	CbGeAlD
Ruxolitinib—PHKG2—medulla oblongata—malignant glioma	0.000593	0.00591	CbGeAlD
Ruxolitinib—DAPK2—medulla oblongata—malignant glioma	0.000583	0.00581	CbGeAlD
Ruxolitinib—GRK1—brain—malignant glioma	0.000583	0.00581	CbGeAlD
Ruxolitinib—CAMK2G—telencephalon—malignant glioma	0.000582	0.0058	CbGeAlD
Ruxolitinib—LRRK2—telencephalon—malignant glioma	0.000577	0.00575	CbGeAlD
Ruxolitinib—PLK3—central nervous system—malignant glioma	0.000576	0.00574	CbGeAlD
Ruxolitinib—JAK2—embryo—malignant glioma	0.000575	0.00573	CbGeAlD
Ruxolitinib—PRKCE—brain—malignant glioma	0.00057	0.00568	CbGeAlD
Ruxolitinib—MAP3K7—retina—malignant glioma	0.000569	0.00567	CbGeAlD
Ruxolitinib—TYK2—retina—malignant glioma	0.000559	0.00557	CbGeAlD
Ruxolitinib—JAK1—midbrain—malignant glioma	0.000558	0.00556	CbGeAlD
Ruxolitinib—DCLK1—midbrain—malignant glioma	0.000558	0.00556	CbGeAlD
Ruxolitinib—MKNK2—retina—malignant glioma	0.000552	0.0055	CbGeAlD
Ruxolitinib—DAPK3—medulla oblongata—malignant glioma	0.000548	0.00546	CbGeAlD
Ruxolitinib—RPS6KA6—brain—malignant glioma	0.000548	0.00546	CbGeAlD
Ruxolitinib—PLK1—brain—malignant glioma	0.000548	0.00546	CbGeAlD
Ruxolitinib—MAST1—brain—malignant glioma	0.000548	0.00546	CbGeAlD
Ruxolitinib—JAK1—spinal cord—malignant glioma	0.000545	0.00543	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—malignant glioma	0.000545	0.00543	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—malignant glioma	0.000539	0.00537	CbGeAlD
Ruxolitinib—DAPK2—midbrain—malignant glioma	0.000533	0.00531	CbGeAlD
Ruxolitinib—MAP3K2—telencephalon—malignant glioma	0.000529	0.00527	CbGeAlD
Ruxolitinib—CAMK1—cerebellum—malignant glioma	0.000527	0.00525	CbGeAlD
Ruxolitinib—MAP3K7—telencephalon—malignant glioma	0.000524	0.00522	CbGeAlD
Ruxolitinib—MARK2—central nervous system—malignant glioma	0.000523	0.00521	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000522	0.0253	CcSEcCtD
Ruxolitinib—DAPK2—spinal cord—malignant glioma	0.00052	0.00518	CbGeAlD
Ruxolitinib—DCLK3—brain—malignant glioma	0.000519	0.00518	CbGeAlD
Ruxolitinib—TYK2—telencephalon—malignant glioma	0.000514	0.00512	CbGeAlD
Ruxolitinib—MARK2—cerebellum—malignant glioma	0.000511	0.00509	CbGeAlD
Ruxolitinib—BMPR2—medulla oblongata—malignant glioma	0.000511	0.00509	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—malignant glioma	0.000509	0.00507	CbGeAlD
Ruxolitinib—MKNK2—telencephalon—malignant glioma	0.000507	0.00506	CbGeAlD
Ruxolitinib—IRAK1—telencephalon—malignant glioma	0.000507	0.00506	CbGeAlD
Ruxolitinib—Pancytopenia—Carmustine—malignant glioma	0.000503	0.0244	CcSEcCtD
Ruxolitinib—DAPK3—midbrain—malignant glioma	0.000501	0.00499	CbGeAlD
Ruxolitinib—Neutropenia—Carmustine—malignant glioma	0.000495	0.024	CcSEcCtD
Ruxolitinib—DAPK3—spinal cord—malignant glioma	0.000489	0.00487	CbGeAlD
Ruxolitinib—Pancytopenia—Temozolomide—malignant glioma	0.000486	0.0236	CcSEcCtD
Ruxolitinib—Neutropenia—Temozolomide—malignant glioma	0.000478	0.0232	CcSEcCtD
Ruxolitinib—TAOK2—cerebellum—malignant glioma	0.000473	0.00471	CbGeAlD
Ruxolitinib—JAK2—telencephalon—malignant glioma	0.000468	0.00466	CbGeAlD
Ruxolitinib—BMPR2—midbrain—malignant glioma	0.000467	0.00465	CbGeAlD
Ruxolitinib—Weight increased—Temozolomide—malignant glioma	0.000466	0.0226	CcSEcCtD
Ruxolitinib—TAOK3—brainstem—malignant glioma	0.000463	0.00462	CbGeAlD
Ruxolitinib—Weight decreased—Temozolomide—malignant glioma	0.000463	0.0225	CcSEcCtD
Ruxolitinib—Urinary tract infection—Carmustine—malignant glioma	0.000459	0.0223	CcSEcCtD
Ruxolitinib—CAMK2G—medulla oblongata—malignant glioma	0.000457	0.00456	CbGeAlD
Ruxolitinib—PLK3—brain—malignant glioma	0.000457	0.00456	CbGeAlD
Ruxolitinib—Infestation NOS—Temozolomide—malignant glioma	0.000456	0.0221	CcSEcCtD
Ruxolitinib—Infestation—Temozolomide—malignant glioma	0.000456	0.0221	CcSEcCtD
Ruxolitinib—LRRK2—medulla oblongata—malignant glioma	0.000453	0.00452	CbGeAlD
Ruxolitinib—TAOK3—retina—malignant glioma	0.000447	0.00445	CbGeAlD
Ruxolitinib—JAK3—central nervous system—malignant glioma	0.000445	0.00443	CbGeAlD
Ruxolitinib—Urinary tract infection—Temozolomide—malignant glioma	0.000443	0.0215	CcSEcCtD
Ruxolitinib—JAK1—central nervous system—malignant glioma	0.000442	0.0044	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—malignant glioma	0.000442	0.0044	CbGeAlD
Ruxolitinib—LTK—brain—malignant glioma	0.000442	0.0044	CbGeAlD
Ruxolitinib—JAK3—cerebellum—malignant glioma	0.000435	0.00433	CbGeAlD
Ruxolitinib—DCLK1—cerebellum—malignant glioma	0.000432	0.0043	CbGeAlD
Ruxolitinib—JAK1—cerebellum—malignant glioma	0.000432	0.0043	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000432	0.0209	CcSEcCtD
Ruxolitinib—CAMK1D—central nervous system—malignant glioma	0.000431	0.0043	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—malignant glioma	0.000429	0.00427	CbGeAlD
Ruxolitinib—CAMK1—brain—malignant glioma	0.000428	0.00426	CbGeAlD
Ruxolitinib—Haemoglobin—Carmustine—malignant glioma	0.000426	0.0207	CcSEcCtD
Ruxolitinib—Haemorrhage—Carmustine—malignant glioma	0.000424	0.0206	CcSEcCtD
Ruxolitinib—CAMK1D—cerebellum—malignant glioma	0.000422	0.0042	CbGeAlD
Ruxolitinib—PHKG2—cerebellum—malignant glioma	0.000419	0.00418	CbGeAlD
Ruxolitinib—BMP2K—midbrain—malignant glioma	0.000418	0.00417	CbGeAlD
Ruxolitinib—CAMK2G—midbrain—malignant glioma	0.000418	0.00417	CbGeAlD
Ruxolitinib—MARK2—brain—malignant glioma	0.000415	0.00414	CbGeAlD
Ruxolitinib—STK16—central nervous system—malignant glioma	0.000415	0.00413	CbGeAlD
Ruxolitinib—LRRK2—midbrain—malignant glioma	0.000414	0.00413	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—malignant glioma	0.000413	0.00411	CbGeAlD
Ruxolitinib—DAPK2—cerebellum—malignant glioma	0.000412	0.00411	CbGeAlD
Ruxolitinib—Haemoglobin—Temozolomide—malignant glioma	0.000412	0.02	CcSEcCtD
Ruxolitinib—MAP3K7—medulla oblongata—malignant glioma	0.000411	0.0041	CbGeAlD
Ruxolitinib—TAOK3—telencephalon—malignant glioma	0.000411	0.0041	CbGeAlD
Ruxolitinib—Haemorrhage—Temozolomide—malignant glioma	0.00041	0.0199	CcSEcCtD
Ruxolitinib—BMP2K—spinal cord—malignant glioma	0.000408	0.00406	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—malignant glioma	0.000408	0.00406	CbGeAlD
Ruxolitinib—STK16—cerebellum—malignant glioma	0.000405	0.00404	CbGeAlD
Ruxolitinib—MAP3K19—central nervous system—malignant glioma	0.000404	0.00403	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—malignant glioma	0.000404	0.00403	CbGeAlD
Ruxolitinib—TYK2—medulla oblongata—malignant glioma	0.000404	0.00403	CbGeAlD
Ruxolitinib—HIPK2—cerebellum—malignant glioma	0.000403	0.00402	CbGeAlD
Ruxolitinib—MKNK2—medulla oblongata—malignant glioma	0.000399	0.00397	CbGeAlD
Ruxolitinib—DAPK3—central nervous system—malignant glioma	0.000396	0.00395	CbGeAlD
Ruxolitinib—CLK2—central nervous system—malignant glioma	0.000393	0.00391	CbGeAlD
Ruxolitinib—RET—medulla oblongata—malignant glioma	0.000389	0.00387	CbGeAlD
Ruxolitinib—DAPK3—cerebellum—malignant glioma	0.000387	0.00386	CbGeAlD
Ruxolitinib—TAOK2—brain—malignant glioma	0.000384	0.00383	CbGeAlD
Ruxolitinib—CLK2—cerebellum—malignant glioma	0.000384	0.00382	CbGeAlD
Ruxolitinib—ROCK1—central nervous system—malignant glioma	0.000381	0.00379	CbGeAlD
Ruxolitinib—MAP3K7—midbrain—malignant glioma	0.000376	0.00375	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—malignant glioma	0.000371	0.0037	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—malignant glioma	0.00037	0.00368	CbGeAlD
Ruxolitinib—TYK2—midbrain—malignant glioma	0.000369	0.00368	CbGeAlD
Ruxolitinib—Malnutrition—Carmustine—malignant glioma	0.000369	0.0179	CcSEcCtD
Ruxolitinib—JAK2—medulla oblongata—malignant glioma	0.000368	0.00366	CbGeAlD
Ruxolitinib—MAP3K7—spinal cord—malignant glioma	0.000367	0.00366	CbGeAlD
Ruxolitinib—IRAK1—midbrain—malignant glioma	0.000364	0.00363	CbGeAlD
Ruxolitinib—MKNK2—midbrain—malignant glioma	0.000364	0.00363	CbGeAlD
Ruxolitinib—DYRK1A—cerebellum—malignant glioma	0.000363	0.00362	CbGeAlD
Ruxolitinib—BMPR2—cerebellum—malignant glioma	0.000361	0.0036	CbGeAlD
Ruxolitinib—TYK2—spinal cord—malignant glioma	0.00036	0.00359	CbGeAlD
Ruxolitinib—Malnutrition—Temozolomide—malignant glioma	0.000357	0.0173	CcSEcCtD
Ruxolitinib—MKNK2—spinal cord—malignant glioma	0.000356	0.00354	CbGeAlD
Ruxolitinib—RET—midbrain—malignant glioma	0.000355	0.00354	CbGeAlD
Ruxolitinib—MAP3K3—medulla oblongata—malignant glioma	0.000354	0.00353	CbGeAlD
Ruxolitinib—JAK3—brain—malignant glioma	0.000353	0.00352	CbGeAlD
Ruxolitinib—JAK1—brain—malignant glioma	0.000351	0.0035	CbGeAlD
Ruxolitinib—DCLK1—brain—malignant glioma	0.000351	0.0035	CbGeAlD
Ruxolitinib—PLK4—brain—malignant glioma	0.000349	0.00347	CbGeAlD
Ruxolitinib—RET—spinal cord—malignant glioma	0.000347	0.00346	CbGeAlD
Ruxolitinib—NUAK2—cerebellum—malignant glioma	0.000345	0.00344	CbGeAlD
Ruxolitinib—CAMK1D—brain—malignant glioma	0.000342	0.00341	CbGeAlD
Ruxolitinib—Anaemia—Carmustine—malignant glioma	0.000341	0.0165	CcSEcCtD
Ruxolitinib—PHKG2—brain—malignant glioma	0.00034	0.00339	CbGeAlD
Ruxolitinib—DAPK2—brain—malignant glioma	0.000335	0.00334	CbGeAlD
Ruxolitinib—BMP2K—central nervous system—malignant glioma	0.000331	0.0033	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—malignant glioma	0.000331	0.0033	CbGeAlD
Ruxolitinib—Anaemia—Temozolomide—malignant glioma	0.00033	0.016	CcSEcCtD
Ruxolitinib—STK16—brain—malignant glioma	0.000329	0.00328	CbGeAlD
Ruxolitinib—LRRK2—central nervous system—malignant glioma	0.000328	0.00327	CbGeAlD
Ruxolitinib—JAK2—spinal cord—malignant glioma	0.000328	0.00327	CbGeAlD
Ruxolitinib—HIPK2—brain—malignant glioma	0.000328	0.00326	CbGeAlD
Ruxolitinib—MAP3K3—midbrain—malignant glioma	0.000324	0.00323	CbGeAlD
Ruxolitinib—CAMK2G—cerebellum—malignant glioma	0.000323	0.00322	CbGeAlD
Ruxolitinib—BMP2K—cerebellum—malignant glioma	0.000323	0.00322	CbGeAlD
Ruxolitinib—TAOK3—medulla oblongata—malignant glioma	0.000323	0.00322	CbGeAlD
Ruxolitinib—MAP3K19—brain—malignant glioma	0.000321	0.0032	CbGeAlD
Ruxolitinib—LRRK2—cerebellum—malignant glioma	0.00032	0.00319	CbGeAlD
Ruxolitinib—MAP3K3—spinal cord—malignant glioma	0.000316	0.00315	CbGeAlD
Ruxolitinib—DAPK3—brain—malignant glioma	0.000315	0.00314	CbGeAlD
Ruxolitinib—CLK2—brain—malignant glioma	0.000312	0.00311	CbGeAlD
Ruxolitinib—ROCK1—brain—malignant glioma	0.000302	0.00301	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000301	0.0146	CcSEcCtD
Ruxolitinib—MAP3K2—central nervous system—malignant glioma	0.0003	0.00299	CbGeAlD
Ruxolitinib—Infection—Carmustine—malignant glioma	0.000299	0.0145	CcSEcCtD
Ruxolitinib—TAOK3—midbrain—malignant glioma	0.000295	0.00294	CbGeAlD
Ruxolitinib—Thrombocytopenia—Carmustine—malignant glioma	0.000295	0.0143	CcSEcCtD
Ruxolitinib—DYRK1A—brain—malignant glioma	0.000295	0.00294	CbGeAlD
Ruxolitinib—MAP3K2—cerebellum—malignant glioma	0.000294	0.00293	CbGeAlD
Ruxolitinib—BMPR2—brain—malignant glioma	0.000293	0.00292	CbGeAlD
Ruxolitinib—TYK2—central nervous system—malignant glioma	0.000292	0.00291	CbGeAlD
Ruxolitinib—MAP3K7—cerebellum—malignant glioma	0.000291	0.0029	CbGeAlD
Ruxolitinib—Infection—Temozolomide—malignant glioma	0.000289	0.014	CcSEcCtD
Ruxolitinib—MKNK2—central nervous system—malignant glioma	0.000288	0.00287	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—malignant glioma	0.000288	0.00287	CbGeAlD
Ruxolitinib—TYK2—cerebellum—malignant glioma	0.000286	0.00285	CbGeAlD
Ruxolitinib—Nervous system disorder—Temozolomide—malignant glioma	0.000285	0.0138	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Temozolomide—malignant glioma	0.000285	0.0138	CcSEcCtD
Ruxolitinib—Skin disorder—Temozolomide—malignant glioma	0.000283	0.0137	CcSEcCtD
Ruxolitinib—MKNK2—cerebellum—malignant glioma	0.000282	0.00281	CbGeAlD
Ruxolitinib—IRAK1—cerebellum—malignant glioma	0.000282	0.00281	CbGeAlD
Ruxolitinib—RET—central nervous system—malignant glioma	0.000281	0.0028	CbGeAlD
Ruxolitinib—NUAK2—brain—malignant glioma	0.00028	0.00279	CbGeAlD
Ruxolitinib—RET—cerebellum—malignant glioma	0.000275	0.00274	CbGeAlD
Ruxolitinib—JAK2—central nervous system—malignant glioma	0.000266	0.00265	CbGeAlD
Ruxolitinib—CAMK2G—brain—malignant glioma	0.000263	0.00262	CbGeAlD
Ruxolitinib—BMP2K—brain—malignant glioma	0.000263	0.00262	CbGeAlD
Ruxolitinib—LRRK2—brain—malignant glioma	0.00026	0.00259	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.00026	0.0126	CcSEcCtD
Ruxolitinib—JAK2—cerebellum—malignant glioma	0.00026	0.00259	CbGeAlD
Ruxolitinib—MAP3K3—central nervous system—malignant glioma	0.000256	0.00255	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000251	0.0122	CcSEcCtD
Ruxolitinib—Fatigue—Temozolomide—malignant glioma	0.000251	0.0122	CcSEcCtD
Ruxolitinib—MAP3K3—cerebellum—malignant glioma	0.00025	0.0025	CbGeAlD
Ruxolitinib—MAP3K2—brain—malignant glioma	0.000238	0.00238	CbGeAlD
Ruxolitinib—Body temperature increased—Carmustine—malignant glioma	0.000238	0.0115	CcSEcCtD
Ruxolitinib—MAP3K7—brain—malignant glioma	0.000236	0.00235	CbGeAlD
Ruxolitinib—TAOK3—central nervous system—malignant glioma	0.000234	0.00233	CbGeAlD
Ruxolitinib—TYK2—brain—malignant glioma	0.000232	0.00231	CbGeAlD
Ruxolitinib—Body temperature increased—Temozolomide—malignant glioma	0.00023	0.0112	CcSEcCtD
Ruxolitinib—MKNK2—brain—malignant glioma	0.000229	0.00228	CbGeAlD
Ruxolitinib—IRAK1—brain—malignant glioma	0.000229	0.00228	CbGeAlD
Ruxolitinib—TAOK3—cerebellum—malignant glioma	0.000228	0.00228	CbGeAlD
Ruxolitinib—RET—brain—malignant glioma	0.000223	0.00223	CbGeAlD
Ruxolitinib—Asthenia—Carmustine—malignant glioma	0.000216	0.0105	CcSEcCtD
Ruxolitinib—JAK2—brain—malignant glioma	0.000211	0.0021	CbGeAlD
Ruxolitinib—Asthenia—Temozolomide—malignant glioma	0.000209	0.0101	CcSEcCtD
Ruxolitinib—Pruritus—Temozolomide—malignant glioma	0.000206	0.00999	CcSEcCtD
Ruxolitinib—MAP3K3—brain—malignant glioma	0.000203	0.00203	CbGeAlD
Ruxolitinib—Dizziness—Carmustine—malignant glioma	0.000199	0.00966	CcSEcCtD
Ruxolitinib—Dizziness—Temozolomide—malignant glioma	0.000192	0.00934	CcSEcCtD
Ruxolitinib—Headache—Carmustine—malignant glioma	0.000189	0.00915	CcSEcCtD
Ruxolitinib—TAOK3—brain—malignant glioma	0.000185	0.00185	CbGeAlD
Ruxolitinib—Headache—Temozolomide—malignant glioma	0.000182	0.00884	CcSEcCtD
Ruxolitinib—CYP3A4—central nervous system—malignant glioma	7.1e-05	0.000707	CbGeAlD
Ruxolitinib—MAP3K7—Immune System—PTEN—malignant glioma	2.08e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOTCH1—malignant glioma	2.08e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT2—malignant glioma	2.08e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGF—malignant glioma	2.07e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FGF2—malignant glioma	2.07e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—malignant glioma	2.06e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—malignant glioma	2.06e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CB—malignant glioma	2.06e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—malignant glioma	2.06e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTPN11—malignant glioma	2.06e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL8—malignant glioma	2.06e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PIK3CA—malignant glioma	2.05e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PDGFRA—malignant glioma	2.05e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CD80—malignant glioma	2.04e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APC—malignant glioma	2.03e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CG—malignant glioma	2.03e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BRAF—malignant glioma	2.03e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—malignant glioma	2.02e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGF—malignant glioma	2.01e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—malignant glioma	2e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—malignant glioma	2e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTPN11—malignant glioma	2e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CD—malignant glioma	1.99e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SPP1—malignant glioma	1.99e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—malignant glioma	1.99e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—malignant glioma	1.99e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTEN—malignant glioma	1.98e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—malignant glioma	1.98e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—malignant glioma	1.98e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—malignant glioma	1.98e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT2—malignant glioma	1.98e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—malignant glioma	1.97e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—malignant glioma	1.97e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BRAF—malignant glioma	1.97e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—malignant glioma	1.97e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—malignant glioma	1.96e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2—malignant glioma	1.96e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—malignant glioma	1.95e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—malignant glioma	1.95e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNG—malignant glioma	1.95e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MDM2—malignant glioma	1.93e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—RAF1—malignant glioma	1.93e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—malignant glioma	1.92e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT2—malignant glioma	1.92e-06	1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BRAF—malignant glioma	1.91e-06	1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—malignant glioma	1.91e-06	1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FGF2—malignant glioma	1.91e-06	1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—malignant glioma	1.91e-06	9.99e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CD—malignant glioma	1.9e-06	9.94e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—malignant glioma	1.89e-06	9.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—malignant glioma	1.89e-06	9.91e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—malignant glioma	1.89e-06	9.91e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TERT—malignant glioma	1.89e-06	9.88e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CB—malignant glioma	1.88e-06	9.86e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTEN—malignant glioma	1.88e-06	9.85e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—malignant glioma	1.86e-06	9.75e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT2—malignant glioma	1.86e-06	9.74e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—malignant glioma	1.86e-06	9.74e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTEN—malignant glioma	1.85e-06	9.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CD—malignant glioma	1.84e-06	9.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PDGFB—malignant glioma	1.84e-06	9.64e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—malignant glioma	1.83e-06	9.61e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGFR1—malignant glioma	1.83e-06	9.59e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—malignant glioma	1.83e-06	9.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—malignant glioma	1.82e-06	9.55e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FGF2—malignant glioma	1.82e-06	9.52e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—malignant glioma	1.82e-06	9.51e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—malignant glioma	1.8e-06	9.45e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—malignant glioma	1.8e-06	9.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HIF1A—malignant glioma	1.8e-06	9.45e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—malignant glioma	1.8e-06	9.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—malignant glioma	1.79e-06	9.37e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CD—malignant glioma	1.79e-06	9.36e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MDM2—malignant glioma	1.79e-06	9.36e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—RAF1—malignant glioma	1.78e-06	9.33e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—malignant glioma	1.78e-06	9.3e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—malignant glioma	1.77e-06	9.28e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—malignant glioma	1.77e-06	9.26e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FGF2—malignant glioma	1.76e-06	9.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—malignant glioma	1.76e-06	9.23e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—malignant glioma	1.74e-06	9.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CAV1—malignant glioma	1.74e-06	9.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CB—malignant glioma	1.74e-06	9.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—malignant glioma	1.74e-06	9.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—malignant glioma	1.73e-06	9.06e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KDR—malignant glioma	1.72e-06	9.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—malignant glioma	1.72e-06	9.02e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—IDH2—malignant glioma	1.72e-06	9.02e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGF2—malignant glioma	1.71e-06	8.96e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MDM2—malignant glioma	1.7e-06	8.91e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—malignant glioma	1.7e-06	8.89e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—malignant glioma	1.7e-06	8.89e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RAF1—malignant glioma	1.69e-06	8.88e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—malignant glioma	1.69e-06	8.86e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—malignant glioma	1.68e-06	8.81e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—malignant glioma	1.68e-06	8.79e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—malignant glioma	1.68e-06	8.78e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—malignant glioma	1.68e-06	8.78e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—malignant glioma	1.67e-06	8.75e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—F2—malignant glioma	1.66e-06	8.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FN1—malignant glioma	1.66e-06	8.7e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—malignant glioma	1.66e-06	8.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CB—malignant glioma	1.65e-06	8.67e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—malignant glioma	1.65e-06	8.66e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MDM2—malignant glioma	1.65e-06	8.65e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—malignant glioma	1.65e-06	8.63e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—malignant glioma	1.65e-06	8.63e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RAF1—malignant glioma	1.64e-06	8.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BAD—malignant glioma	1.64e-06	8.59e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—malignant glioma	1.63e-06	8.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—malignant glioma	1.63e-06	8.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH1—malignant glioma	1.62e-06	8.51e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2B6—malignant glioma	1.62e-06	8.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—malignant glioma	1.61e-06	8.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—malignant glioma	1.61e-06	8.43e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CB—malignant glioma	1.61e-06	8.41e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MDM2—malignant glioma	1.6e-06	8.39e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—malignant glioma	1.6e-06	8.37e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RAF1—malignant glioma	1.6e-06	8.36e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CD80—malignant glioma	1.59e-06	8.34e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—malignant glioma	1.59e-06	8.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—malignant glioma	1.59e-06	8.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—malignant glioma	1.59e-06	8.32e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—malignant glioma	1.58e-06	8.27e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGF—malignant glioma	1.57e-06	8.23e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—malignant glioma	1.56e-06	8.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTPN11—malignant glioma	1.56e-06	8.18e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—malignant glioma	1.56e-06	8.17e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—malignant glioma	1.56e-06	8.16e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—malignant glioma	1.55e-06	8.1e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—malignant glioma	1.54e-06	8.08e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—malignant glioma	1.54e-06	8.08e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—malignant glioma	1.54e-06	8.05e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—malignant glioma	1.53e-06	8e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—malignant glioma	1.52e-06	7.97e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—malignant glioma	1.52e-06	7.97e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—malignant glioma	1.52e-06	7.96e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—malignant glioma	1.51e-06	7.93e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—malignant glioma	1.5e-06	7.87e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—malignant glioma	1.5e-06	7.87e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—malignant glioma	1.5e-06	7.84e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—malignant glioma	1.49e-06	7.82e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—malignant glioma	1.49e-06	7.82e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—malignant glioma	1.49e-06	7.81e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—IDH1—malignant glioma	1.48e-06	7.76e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—malignant glioma	1.48e-06	7.74e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—malignant glioma	1.47e-06	7.73e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—malignant glioma	1.47e-06	7.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—malignant glioma	1.45e-06	7.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT2—malignant glioma	1.45e-06	7.61e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—malignant glioma	1.45e-06	7.58e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—malignant glioma	1.44e-06	7.56e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—malignant glioma	1.44e-06	7.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—malignant glioma	1.43e-06	7.51e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SPHK1—malignant glioma	1.43e-06	7.51e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—malignant glioma	1.43e-06	7.49e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—malignant glioma	1.43e-06	7.49e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—malignant glioma	1.42e-06	7.44e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2C18—malignant glioma	1.4e-06	7.35e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—malignant glioma	1.4e-06	7.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—malignant glioma	1.4e-06	7.32e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—malignant glioma	1.4e-06	7.31e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—malignant glioma	1.39e-06	7.27e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—malignant glioma	1.38e-06	7.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—malignant glioma	1.37e-06	7.16e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—malignant glioma	1.35e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—malignant glioma	1.35e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—malignant glioma	1.35e-06	7.05e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—malignant glioma	1.34e-06	7.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGF2—malignant glioma	1.34e-06	7e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—malignant glioma	1.33e-06	6.95e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—malignant glioma	1.32e-06	6.93e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—malignant glioma	1.3e-06	6.83e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—malignant glioma	1.29e-06	6.76e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—malignant glioma	1.28e-06	6.72e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—malignant glioma	1.28e-06	6.7e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—malignant glioma	1.27e-06	6.68e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—malignant glioma	1.26e-06	6.61e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—malignant glioma	1.26e-06	6.6e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—malignant glioma	1.26e-06	6.58e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—malignant glioma	1.25e-06	6.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MDM2—malignant glioma	1.25e-06	6.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—malignant glioma	1.25e-06	6.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—malignant glioma	1.25e-06	6.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RAF1—malignant glioma	1.25e-06	6.53e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—malignant glioma	1.24e-06	6.5e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—malignant glioma	1.24e-06	6.48e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—malignant glioma	1.23e-06	6.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—malignant glioma	1.22e-06	6.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—malignant glioma	1.22e-06	6.38e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—malignant glioma	1.22e-06	6.37e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—malignant glioma	1.2e-06	6.31e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—malignant glioma	1.2e-06	6.29e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—malignant glioma	1.19e-06	6.22e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—malignant glioma	1.17e-06	6.13e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—malignant glioma	1.16e-06	6.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—malignant glioma	1.15e-06	6.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—malignant glioma	1.15e-06	6.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—malignant glioma	1.15e-06	6.01e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—malignant glioma	1.14e-06	5.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—malignant glioma	1.14e-06	5.95e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—malignant glioma	1.13e-06	5.92e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—malignant glioma	1.13e-06	5.91e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—malignant glioma	1.12e-06	5.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—malignant glioma	1.12e-06	5.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—malignant glioma	1.12e-06	5.86e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—malignant glioma	1.1e-06	5.75e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—malignant glioma	1.09e-06	5.73e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—malignant glioma	1.08e-06	5.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—malignant glioma	1.07e-06	5.58e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—malignant glioma	1.07e-06	5.58e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS1—malignant glioma	1.06e-06	5.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—malignant glioma	1.06e-06	5.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—malignant glioma	1.06e-06	5.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—malignant glioma	1.05e-06	5.51e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—malignant glioma	1.03e-06	5.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—malignant glioma	1.03e-06	5.38e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—malignant glioma	1.01e-06	5.28e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BCHE—malignant glioma	9.89e-07	5.18e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—malignant glioma	9.79e-07	5.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	9.77e-07	5.12e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—malignant glioma	9.76e-07	5.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—malignant glioma	9.5e-07	4.98e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—malignant glioma	9.5e-07	4.97e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—malignant glioma	9.47e-07	4.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—malignant glioma	9.41e-07	4.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—malignant glioma	9.37e-07	4.91e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—malignant glioma	9.19e-07	4.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—malignant glioma	8.74e-07	4.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—malignant glioma	8.66e-07	4.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—malignant glioma	8.55e-07	4.48e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—malignant glioma	8.24e-07	4.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—malignant glioma	8.08e-07	4.23e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—malignant glioma	8e-07	4.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—malignant glioma	7.87e-07	4.12e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—malignant glioma	7.76e-07	4.06e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAT—malignant glioma	7.66e-07	4.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—malignant glioma	7.42e-07	3.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOR1—malignant glioma	7.23e-07	3.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—malignant glioma	7.18e-07	3.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—malignant glioma	6.06e-07	3.18e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAV1—malignant glioma	5.89e-07	3.09e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	5.37e-07	2.81e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—malignant glioma	5.18e-07	2.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	4.72e-07	2.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	4.11e-07	2.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—malignant glioma	4.08e-07	2.14e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—malignant glioma	3.55e-07	1.86e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	2.51e-07	1.31e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—malignant glioma	2.05e-07	1.07e-06	CbGpPWpGaD
